Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx trial group receives cancer treatment with no adverse effects

VAL201 is being developed to treat hormone-resistant prostate cancer and is currently undergoing a phase I/II study.
ValiRx trial group receives cancer treatment with no adverse effects
VAL201 is being developed to tackle prostate cancer.

ValiRx (LON:VAL) said a further group of patients receiving VAL201 have completed the clinical trial dosing sequence with no significant adverse effects.

VAL201 is being developed to treat hormone-resistant prostate cancer and is currently undergoing a phase I/II study.

The latest feedback echoes that from an earlier cohort on a lower dose of the medication. ValiRx will now be allowed to increase the amount of VAL201 administered to cancer sufferers one last time to assess its impact.

“The company believes that being able to dose patients at levels and with a frequency that matches the pre-clinical validated amounts that are therapeutically relevant, represents another important milestone,” ValiRx said in a short stock exchange statement.

The firm will provide updates as the trial progresses. Eagerly awaited will be any hint of efficacy. Researchers saw “tumour modulating effects” pre-clinically and they have been “hinted at during the in-human stage”.

Ian_55ae0ddd437b7.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Newswire
October 13 2016

Related Articles

drug resistant infections such as E. coli and Pseudomonas
October 02 2016
In vivo testing confirmed that Redx’s novel compounds were highly effective against certain drug resistant strains of bacteria.
Pollen2.jpg
July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.
Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.